Pharmacyclics Inc (PCYC)

PCYC (:Drugs) EQUITY
$261.25
pos +1.70
+0.66%
Today's Range: 260.76 - 261.68 | PCYC Avg Daily Volume: 1,317,600
Last Update: 05/22/15 - 4:00 PM EDT
Volume: 1,953,837
YTD Performance: 0.00%
Open: $260.76
Previous Close: $259.55
52 Week Range: $82.51 - $261.68
Oustanding Shares: 77,079,177
Market Cap: 20,136,934,991
6-Month Chart
TheStreet Ratings Grade for PCYC
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 1 2 2 7
Moderate Buy 0 0 0 0
Hold 9 10 10 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.80 2.67 2.67 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
PCYC Sector Avg. S&P 500
0.00 290.20 26.87
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 180.50 87.63 3.39
Net Income 28.50 -3.45 0.00
EPS 26.80 -2.93 0.00
Earnings for PCYC:
EBITDA 0.13B
Revenue 0.73B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $-0.62 $0.12 $0.08 $4.76
Number of Analysts 7 7 8 8
High Estimate $0.22 $0.79 $1.18 $7.96
Low Estimate $-1.36 $-0.32 $-1.24 $2.45
Prior Year $-0.49 $0.53 $1.09 $0.08
Growth Rate (Year over Year) -27.11% -78.17% -92.43% 5,665.15%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Jun 17, 2015 | 11:25 AM EDT

That this could be such an open secret is beyond me.

By

Jim Cramer

 | Jun 11, 2015 | 2:18 PM EDT

New companies are coming up with major drugs.

By

Jim Cramer

 | May 26, 2015 | 12:34 PM EDT

Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.

By

Jim Cramer

 | May 18, 2015 | 3:24 PM EDT

Acquisitions cut into overabundance of companies.

By

Jim Cramer

 | May 18, 2015 | 12:19 PM EDT

Many of these stocks are off to the races.

By

Jim Cramer

 | May 6, 2015 | 1:33 PM EDT

It's not the Fed chief's place.

By

David Katz

 | Apr 10, 2015 | 8:00 AM EDT

Drug franchises are still going strong.

By

Jim Cramer

 | Apr 8, 2015 | 12:38 PM EDT

The ecstasy and the agony of M&A all in one day.

By

Jim Cramer

 | Mar 31, 2015 | 11:33 AM EDT

Combined Heinz-Kraft heads a long second-quarter list.

By

Jim Cramer

 | Mar 27, 2015 | 12:00 PM EDT

You can't help but feel better about both groups.

$51 billion - How much Uber is valued at in its last financing round. The unicorns keep g...
....put protection is cheap! Seems every time we come down to this 12 or 11 level in VIX ...
Chevron (CVX) and the weak weekly chart, or is it?    Why would anyone want to...

Care to comment on my prior post?

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.